Skip to main content
Premium Trial:

Request an Annual Quote

Roche Acquires Alnylam Lab to Build RNAi Excellence Center; Buys Stake and Forges Alliance

NEW YORK (GenomeWeb News) — Roche plans to buy an Alnylam research facility in Germany, has licensed Alnylam’s RNAi IP, and will work with the RNAi company on drug-discovery projects, Roche said today.
Under the agreement, worth $331 million plus unknown milestones and royalties, Roche will acquire the Alnylam lab in Kulmbach, along with about 40 employees, once the deal is cleared by regulators in around 30 days, Roche said. Roche will use the site to create a Center of Excellence for RNAi therapeutics research.
The non-exclusive license, meantime, will give Roche access to Alnylam’s RNAi IP for use in drug research.
The companies will collaborate on one or more disease targets that have yet to be determined in exchange for royalty payments.
The agreement calls for Roche to pay Alnylam $331 million in up-front cash plus an equity investment for 1.975 million shares of Alnylam’s common stock at $21.50 a share, or just under five percent of Alnylam’s outstanding shares.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.